JP2004509149A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509149A5
JP2004509149A5 JP2002528294A JP2002528294A JP2004509149A5 JP 2004509149 A5 JP2004509149 A5 JP 2004509149A5 JP 2002528294 A JP2002528294 A JP 2002528294A JP 2002528294 A JP2002528294 A JP 2002528294A JP 2004509149 A5 JP2004509149 A5 JP 2004509149A5
Authority
JP
Japan
Prior art keywords
composition
cell
preparation according
tuberculosis
cell epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002528294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509149A (ja
JP5102930B2 (ja
Filing date
Publication date
Priority claimed from GBGB0023203.3A external-priority patent/GB0023203D0/en
Application filed filed Critical
Publication of JP2004509149A publication Critical patent/JP2004509149A/ja
Publication of JP2004509149A5 publication Critical patent/JP2004509149A5/ja
Application granted granted Critical
Publication of JP5102930B2 publication Critical patent/JP5102930B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002528294A 2000-09-21 2001-09-13 ワクチン接種方法 Expired - Lifetime JP5102930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0023203.3A GB0023203D0 (en) 2000-09-21 2000-09-21 Vaccination method
GB0023203.3 2000-09-21
PCT/GB2001/004116 WO2002024224A2 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen

Publications (3)

Publication Number Publication Date
JP2004509149A JP2004509149A (ja) 2004-03-25
JP2004509149A5 true JP2004509149A5 (https=) 2008-11-20
JP5102930B2 JP5102930B2 (ja) 2012-12-19

Family

ID=9899889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002528294A Expired - Lifetime JP5102930B2 (ja) 2000-09-21 2001-09-13 ワクチン接種方法

Country Status (10)

Country Link
US (1) US20040018177A1 (https=)
EP (1) EP1320379B8 (https=)
JP (1) JP5102930B2 (https=)
AT (1) ATE465750T1 (https=)
AU (2) AU8610901A (https=)
CA (1) CA2422094C (https=)
DE (1) DE60141969D1 (https=)
ES (1) ES2345604T3 (https=)
GB (2) GB0023203D0 (https=)
WO (1) WO2002024224A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP1450854A2 (en) * 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
NZ536592A (en) 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
EP2125868B1 (en) * 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
CN105753989A (zh) * 2014-12-15 2016-07-13 牛津疫苗医学生物科技（英国）有限公司 人工多抗原融合蛋白及其制备和应用
US10881725B2 (en) 2016-01-29 2021-01-05 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102718353B1 (ko) 2016-10-17 2024-10-15 얀센 파마슈티칼즈, 인코포레이티드 재조합 바이러스 레플리콘 시스템 및 그의 용도
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
CN111741766A (zh) 2017-12-19 2020-10-02 杨森科学爱尔兰无限公司 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
KR20210074314A (ko) 2018-10-08 2021-06-21 얀센 파마슈티칼즈, 인코포레이티드 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025533541A (ja) * 2022-09-23 2025-10-07 ビオンテック・ソシエタス・エウロパエア 肝病期抗原の送達のための組成物及び関連方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf

Similar Documents

Publication Publication Date Title
JP2004509149A5 (https=)
Zhang et al. Rational development of multicomponent mRNA vaccine candidates against mpox
Sable et al. Tuberculosis vaccine development: progress in clinical evaluation
Delany et al. Vaccines for the 21st century
CA2422094A1 (en) Vaccination method
Moorthy et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
Britton et al. Improving vaccines against tuberculosis
Excler et al. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines
Robinson et al. T cell vaccines for microbial infections
Wille-Reece et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
Kanesa-thasan et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus—poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans
US7273605B2 (en) Vaccine
Reed et al. Prospects for a better vaccine against tuberculosis
CA2573702A1 (en) Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
Wilck et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
JP2004512269A5 (https=)
Radošević et al. Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects
Wang et al. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120
JP2001514000A5 (https=)
Plotkin Six revolutions in vaccinology
Andrieu et al. Mucosal SIV vaccines comprising inactivated virus particles and bacterial adjuvants induce CD8+ T-regulatory cells that suppress SIV-positive CD4+ T-cell activation and prevent SIV infection in the macaque model
Convit et al. The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis
Feng et al. Induction of CD8+ T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus
Zubair et al. Clinical trials and recent progress in HIV vaccine development
CN105709221A (zh) 用于预防和/或治疗人中的hiv疾病的药物组合物